Glycyrrhizic Acid Suppresses the Development of Precancerous Lesions via Regulating the Hyperproliferation, Inflammation, Angiogenesis and Apoptosis in the Colon of Wistar Rats

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Khan, Rehan ^a   Khan, Abdul Quaiyoom ^a   Lateef, Abdul ^a   Rehman, Muneeb U ^a   Tahir, Mir ^a   Ali, Farrah ^a   Hamiza, Oday O ^a   Sultana, Sarwat ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CASPASE 3; CASPASE 9; CONNEXIN 43; CYCLOOXYGENASE 2; GLYCYRRHIZIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; KI 67 ANTIGEN; PROTEIN P53; SIALOMUCIN; SULFOMUCIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL INFILTRATION; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFICACY; MALE; MAST CELL; NONHUMAN; PRECANCER; RAT;

ABERRANT CRYPT FOCI; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COLON; COLORECTAL NEOPLASMS; CONNEXIN 43; DIMETHYLHYDRAZINES; GLYCYRRHIZIC ACID; MALE; MAST CELLS; MUCINS; RATS; RATS, WISTAR; SIALOMUCINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874007222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056020     Document Type: Article

References (73)

1. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics. CA Cancer J Clin 59: 225-249.
3. Janne PA, Mayer RJ, (2000) Chemoprevention of colorectal cancer. N Engl J Med 342(26): 1960-1968.
4. Khan R, Sultana S, (2011) Farnesol attenuates 1,2-dimethylhydrazine induced oxidative stress, inflammation and apoptotic responses in the colon of Wistar rats. Chem Biol Interact 192: 193-200.
5. Mori H, Hata K, Yamada Y, Kuno T, Hara A, (2005) Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem Biol Interact 155: 1-9.
6. Bird RP, (1987) Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-151.
7. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, et al. (1991) Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 51: 1564-1567.
8. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR, (1991) Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 22: 287-294.
9. Nucci MR, Robinson CR, Longo P, Campbell P, Hamilton SR, (1997) Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum Pathol 28: 1396-1407.
10. Paulsen JE, Løberg EM, Olstørn HB, Knutsen H, Steffensen IL, et al. (2005) Flat dysplastic aberrant crypt foci are related to tumorigenesis in the colon of azoxymethane-treated rat. Cancer Res 65: 121-129.
11. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, et al. (1994) Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54: 5523-5526.
12. Siu IM, Pretlow TG, Amini SB, Pretlow TP, (1997) Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol 150: 1805-1813.
13. Pretlow TP, Cheter C, O'Riordan MA, (1994) Aberrant crypt foci and colon tumors in F344 rats have similar increases in proliferative activity. Int J Cancer 56: 599-602.
14. Bird PR, (1995) Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93: 55-71.
15. Stopera SA, Bird RP, (1992a) Expression of ras oncogene mRNA and protein in aberrant crypt foci. Carcinogenesis 13: 1863-1868.
16. Stopera SA, Murphy LC, Bird RP, (1992b) Evidence for a ras gene mutation in azoxymethane-induced colonie aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer. Carcinogenesis 13: 2081-2085.
17. Vivona AA, Shpitz B, Medline A, Bruce WR, Hay K, et al. (1993) K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 14: 1777-1781.
18. Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL, (1993) K-ras mutation in putative preneoplastic lesions in human colon. J Natl Cancer Inst 85: 2004-2007.
19. Stopera SA, Davie JR, Bird RP, (1992c) Colonie aberrant crypt foci are associated with increased expression of c-fos: the possible role of modified c-fos expression in preneoplastic lesions in colon cancer. Carcinogenesis 13: 573-578.
20. Paulsen JE, Steffensen IL, Løberg EM, Husøy T, Namork E, et al. (2001) Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res 61: 5010-5015.
21. Caderni G, Femia AP, Giannini A, Favuzza A, Luceri C, et al. (2003) Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 63: 2388-2392.
22. Femia AP, Giannini A, Fazi M, Tarquini E, Salvadori M, et al. (2008a) Identification of mucin depleted foci in the human colon. Cancer Prev Res 1: 562-567.
23. Sakai E, Morioka T, Yamada E, Ohkubo H, Higurashi T, et al. (2011) Identification of preneoplastic lesions as mucin-depleted foci in patients with sporadic colorectal cancer. Cancer Sci 103: 144-149.
24. Femia AP, Dolara P, Giannini A, Salvadori M, Biggeri A, et al. (2007) Frequent mutation of Apc gene in rat colon tumorsand mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis. Cancer Res 67: 445-449.
25. Femia AP, Tarquini E, Salvadori M, Ferri S, Giannini A, et al. (2008b) K-ras mutations and mucin profile in preneoplastic lesions and colon tumors induced in rats by 1,2-dimethylhydrazine. Int J Cancer 122: 117-123.
26. Femia AP, Bendinelli B, Giannini A, Salvadori M, Pinzani P, et al. (2005) Mucin-depleted foci have beta-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazinetreated rats. Int J Cancer 116: 9-15.
27. Femia AP, Salvianti F, Luceri C, Dolara P, Salvadori M, et al. (2012) Sustained proliferation and resistance to apoptosis after a cytotoxic insult are early alterations in rat colon carcinogenesis. Int J Cancer 131: 529-536.
28. Femia AP, Dolara P, Luceri C, Salvadori M, Caderni G, (2009) Mucin-depleted foci show strong activation of inflammatory markers in 1,2-dimethylhydrazine-induced carcinogenesis and are promoted by the inflammatory agent sodium dextran sulfate. Int J Cancer 125: 541-547.
29. Femia AP, Caderni G, Bottini C, Salvadori M, Dolara P, et al. (2006) Mucin-depleted foci are modulated by dietary treatments and show deregulation of proliferative activity in carcinogen-treated rodents. Int J Cancer 120: 2301-2305.
30. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
31. Orlowski RZ, Baldwin AS Jr, (2002) NFkappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389.
32. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, et al. (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 104: 19977-19982.
33. Andoh A, Deguchi Y, Inatomi O, Yagi Y, Bamba S, et al. (2006) Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease. Oncol Rep 16: 103-107.
34. He SH, (2004) Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 10: 309-318.
35. Wedemeyer J, Galli SJ, (2005) Decreased susceptibility of mast cell-deficient Kit(W)/Kit(W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab Invest 85: 388-396.
36. Galli SJ, Nakae S, Tsai M, (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6: 135-142.
37. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
38. Wargovich MJ, Jimenez A, McKee K, Steele VE, Velasco M, et al. (2000) Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 21: 1149-1155.
39. Zhang MZ, Xu J, Yao B, Yin H, Cai Q, et al. (2009) Inhibition of 11β-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest 119: 876-885.
40. Pompei R, Flore O, Marccialis MA, Pani A, Loddo B, (1979) Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 281: 689-690.
41. Curreli F, Friedman-Kien AE, Flore O, (2005) Glycyrrhizic acid alters Kaposi sarcoma- associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 115: 642-652.
42. Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, et al. (1999) Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis 20: 59-63.
43. Agarwal R, Wang ZY, Mukhtar H, (1991) Inhibition of mouse skin tumor- initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water. Nutr Cancer 15: 187-193.
44. Yasukawa K, Takido M, Takeuchi M, Nakagawa S, (1988) Inhibitory effect of glycyrrhizin and caffeine on two-stage carcinogenesis in mice. Yakugaku Zasshi 108: 794-796.
45. Takeda S, Ishthara K, Wakui Y, Amagaya S, Maruno M, et al. (1996) Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J Pharm Pharmacol 48(9): 902-905.
46. Okamura N, Miyauchi H, Choshi T, Ishizu T, Yagi A, (2003) Simultaneous determination of glycyrrhizin metabolites formed by the incubation of glycyrrhizin with rat feces by semi-micro high-performance liquid chromatography. Biol Pharm Bull 26(5): 658-661.
47. Hibasami H, Iwase H, Yoshioka K, Takahashi H, (2005) Glycyrrhizin induces apoptosis in human stomach cancer KATO III and human promyelotic leukemia HL-60 cells. Int J Mol Med 16: 233-236.
48. Hibasami H, Iwase H, Yoshioka K, Takahashi H, (2006) Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med 17: 215-219.
49. Thirugnanam S, Xu L, Ramaswamy K, Gnanasekar M, (2008) Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. Oncol Rep 20: 1387-1392.
50. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C, (1983) Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis- double blind trail. Asian Med J 26: 423-438.
51. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, et al. (1997) The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79: 1494-1500.
52. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, et al. (1999) Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14: 1093-1099. incorporate.
53. Khan R, Khan AQ, Qamar W, Lateef A, Tahir M, et al. (2012) Chrysin protects against cisplatin-induced colon. toxicity via amelioration of oxidative stress and apoptosis: probable role of p38MAPK and p53. Toxicol Appl Pharmacol 258(3): 315-329.
54. Cherng JM, Tsai KD, Yu YW, Lin JC, (2011) Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Radiat Res 176: 177-186.
55. Robbe C, Capon C, Coddeville B, Michalski JC, (2004) Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J 384: 307-316.
56. Specian RD, Oliver MG, (1991) Functional biology of intestinal goblet cells. Am J Physiol 260: C183-C193.
57. Filipe MI, Branfoot AC, (1974) Abnormal patterns of mucus secretion in apparently normal mucosa of large intestine with carcinoma. Cancer 34: 282-290.
58. Filipe MI, (1975) Mucus secretion in rat colonic mucosa during carcinogenesis induced by dimethylhydrazine. A morphological and histochemical study. Br J Cancer 32: 60-77.
59. Wargovich MJ, Medline A, Bruce WR, (1983) Early histopathologic events to evolution of colon cancer in C57BL/6 and CFI mice treated with 1.2-dimethylhydrazine. J Natl Cancer Inst 71: 125-131.
60. Sandforth F, Heimpel S, Balzer T, Gutschmidt S, Riecken EO, (1988) Characterization of stereomicroscopically identified preneoplastic lesions during dimethylhydrazine-induced colonic carcinogenesis. Eur J Clin Invest 18: 655-662.
61. Rao BN, Anderson MB, Musser JH, Gilbert JH, Schaefer ME, et al. (1994) Sialyl Lewis X mimics derived from a pharmacophore search are selectin inhibitors with anti-inflammatory activity. J Biol Chem 269: 19663-19666.
62. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, et al. (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14: 431-441.
63. Davis EA, Morris DJ, (1991) Medicinal uses of licorice through the millennia: The good and plenty of it. Mol Cell Endocrinol 78: 1-6.
64. Nakai Y, Nelson WG, DeMarzo AM, (2007) The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res 67: 1378-1384.
65. Theoharides TC, Conti P, (2004) Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25: 235-241.
66. Dimitriadou V, Koutsilieris M, (1997) Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res 17: 1541-1549.
67. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, et al. (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nature Med 13: 1211-1218.
68. Karin M, Greten FR, (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759.
69. Scholzen T, Gerdes J, (2000) "The Ki-67 protein: from the known and the unknown". J Cell Physiol 182: 311-322.
70. Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC, (2003) Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev 83: 1359-1400.
71. Sirnes S, Bruun J, Kolberg M, Kjenseth A, Lind GE, et al. (2011) Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int J Cancer 131: 570-581.
72. Riley T, Sontag E, Chen P, Levine A, (2008) Transcriptional control of human p53- regulated genes. Nat Rev Mol Cell Biol 9: 402-412.
73. Jin S, Levine AJ, (2001) The p53 functional circuit. J Cell Sci 114: 4139-4140.